# A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

> **NCT02549196** · PHASE2 · COMPLETED · sponsor: **Chase Pharmaceuticals Corporation, an affiliate of Allergan plc** · enrollment: 28 (actual)

## Conditions studied

- Dementia of Alzheimer's Type

## Interventions

- **DRUG:** Donepezil
- **DRUG:** Solifenacin

## Key facts

- **NCT ID:** NCT02549196
- **Lead sponsor:** Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-07
- **Primary completion:** 2017-09-28
- **Final completion:** 2017-09-28
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02549196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02549196, "A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02549196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*